What is Enzon Pharmaceuticals Operating Cash Flow per Share?
Enzon Pharmaceuticals's operating cash flow per share for the
three
months ended in Mar. 2024 was $0.00.
Enzon Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.02.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Enzon Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:
During the past 13 years, Enzon Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 88.60% per year. The lowest was -109.40% per year. And the median was -7.70% per year.
ENZN's 3-Year OCF Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.3 * Ranked among companies with meaningful 3-Year OCF Growth Rate only.
Enzon Pharmaceuticals Operating Cash Flow per Share Historical Data
The historical data trend for Enzon Pharmaceuticals's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Enzon Pharmaceuticals Operating Cash Flow per Share Chart
Competitive Comparison of Enzon Pharmaceuticals's Operating Cash Flow per Share
For the Biotechnology subindustry, Enzon Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzon Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Enzon Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Enzon Pharmaceuticals Operating Cash Flow per Share Calculation
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Enzon Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzon Pharmaceuticals Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Enzon Pharmaceuticals (Enzon Pharmaceuticals) Business Description
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENZN has been successfully added to your 